BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
BioCentury | Nov 3, 2017
Financial News

BioGeneration closes Ventures Fund III at EUR82M

On Oct. 31, BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation...
BioCentury | Nov 2, 2017
Finance

Bigger in Benelux

BioGeneration Ventures parlayed two major wins from its second fund into its largest fund to date, and now has the capital reserves for follow-on investments so the firm can retain more value in portfolio companies....
BioCentury | Oct 31, 2017
Financial News

BioGeneration closes third fund

European VC BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation --...
BioCentury | Oct 27, 2017
Clinical News

Amgen discontinues development of CETP inhibitor

Amgen Inc. (NASDAQ:AMGN) discontinued internal development of cholesteryl ester transfer protein (CETP) inhibitor AMG 899 (TA-8995). The company said it will explore out-licensing of the product, which it gained via its 2015 acquisition of Dezima...
BioCentury | Oct 25, 2017
Company News

Amgen raises guidance, discontinues CETP inhibitor

In its 3Q17 earnings late Wednesday, Amgen Inc. (NASDAQ:AMGN) bumped up its 2017 guidance and said it discontinued internal development of cholesteryl ester transfer protein inhibitor AMG 899 . The bellwether pushed its 2017 non-GAAP EPS...
BioCentury | Oct 13, 2017
Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
BioCentury | Oct 12, 2017
Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
BioCentury | Sep 1, 2017
Clinical News

Merck reports additional data for CETP inhibitor in CHD

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL trial in patients with atherosclerotic vascular disease showing that once-daily 100 mg oral anacetrapib (MK-0859) reduced major coronary events -- the primary...
BioCentury | Aug 29, 2017
Clinical News

Merck's CETP inhibitor may miss the mark for CV benefit

Merck & Co. Inc. (NYSE:MRK) reported additional data from the Phase III REVEAL cardiovascular outcomes trial showing that anacetrapib (MK-0859) reduced major coronary events -- the primary endpoint defined as a composite of coronary death,...
Items per page:
1 - 10 of 152